Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10726712 | 0.87 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDKMT2AMEN1 | |
| SCHEMBL4557193 | 0.87 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDKMT2AMEN1 | |
| SCHEMBL17559469 | 0.86 | HPGD (0.61) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL17572996 | 0.86 | ALDH1A1 (0.54) | ALDH1A1GAANPSR1HPGDKMT2A | |
| SCHEMBL17559397 | 0.85 | ALDH1A1 (0.53) | ALDH1A1GAANPSR1HPGDKMT2A | |
| SCHEMBL12302070 | 0.85 | GAA (0.77) | ALDH1A1PKMGAANPSR1HPGD | |
| Lithium Ion SCHEMBL17559395 | 0.83 | ALDH1A1 (0.51) | ALDH1A1PKMGAANPSR1HPGD | |
| SCHEMBL29188760 | 0.82 | KMT2A (0.70) | ALDH1A1PKMGAANPSR1HPGD | |
| SCHEMBL10194850 | 0.80 | PKM (0.72) | ALDH1A1PKMHPGDKMT2AMEN1 | |
| SCHEMBL82433 | 0.80 | ALDH1A1 (0.72) | ALDH1A1PKMHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | ALDH1A1 3487/4885PKM 2601/4885GAA 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.